Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Lipidomics: Opportunities to identify new causal mechanisms and therapeutics for atherosclerosis|
|Citation:||Current Cardiovascular Risk Reports, 2013; 7(1):60-65|
|Puri, R., Duong, M., Kataoka, Y., Uno, K., Nicholls, S.J.|
|Abstract:||A systems biology approach toward biosample analysis has the potential to play an important role in the identification of novel mechanisms of disease. Lipids are fundamental in atherogenesis, and therefore ‘lipidomics’ is likely to become increasingly utilized for biomarker discovery. These biomarkers can be tested for their ability to predict clinical events, superior to current risk prediction algorithms. These biochemical footprints will also serve as potential therapeutic targets for the next generation of anti-atherosclerotic therapies. In a similar fashion, lipidomics will also serve as a future technique for identifying molecular signatures of drug toxicity, and treatment efficacy, much prior to the advent of clinical events. A major challenge for this field is the need for statistical and bioinformatic platforms to evolve in parallel, in order to effectively handle the enormous amount of biochemical data yielded from the high-throughput analysis. Such advances will lead us closer to a more a personalized approach to medical diagnosis and treatment.|
|Keywords:||Lipidomics; New causal mechanisms; The human lipidome; Therapeutics for atherosclerosis|
|Rights:||© 2012 Springer Science+Business Media New York.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.